<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02343094</url>
  </required_header>
  <id_info>
    <org_study_id>2013-003924-35</org_study_id>
    <nct_id>NCT02343094</nct_id>
  </id_info>
  <brief_title>Phenylbutyrate in Proteinuric Nephropathies</brief_title>
  <acronym>PIRATE</acronym>
  <official_title>Phenylbutyrate Effect on Lcn2 Urianry Expression in Proteinuric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether sodium phenylbutyrate can reduce Lcn2&#xD;
      urinary expression in proteinuric patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Proteinuria is a major prognosis factor of chronic kidney disease (CKD) progression.&#xD;
      Convergent evidences from clinical and experimental studies indicate that albuminuria and&#xD;
      proteinuria are not simply a marker of CKD progression, but an active player in the evolution&#xD;
      of the disease. Mechanistically, it has been shown that proteinuria induces endoplasmic&#xD;
      reticulum stress in tubular cells, leading to induction of lipocalin 2/NGAL, a critical&#xD;
      element of CKD progression. Moreover, proteinuric mice treated with phenylbutyrate are&#xD;
      protected from CKD progression.&#xD;
&#xD;
      The aim of this study is to evaluate the efficacy of phenybutyrate, a molecular chaperone&#xD;
      which inhibits ER stress, on the proteinuria-induced NGAL expression. Urinary NGAL/creatinine&#xD;
      ratio will be evaluated in proteinuric patients before and under treatment with&#xD;
      phenylbutyrate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Lcn2/creatinine ratio</measure>
    <time_frame>Day 7, Day 15, Day 21, Day 28</time_frame>
    <description>Reduction of 50 % of Lcn2 concentration, measured with ELISA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary protein/creatinine ratio</measure>
    <time_frame>Day 7</time_frame>
    <description>Reduction of 30% of the proteinurie and the albuminuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary protein/creatinine ratio</measure>
    <time_frame>Day 15</time_frame>
    <description>Reduction of 30% of the proteinurie and the albuminuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary protein/creatinine ratio</measure>
    <time_frame>Day 21</time_frame>
    <description>Reduction of 30% of the proteinurie and the albuminuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary protein/creatinine ratio</measure>
    <time_frame>Day 28</time_frame>
    <description>Reduction of 30% of the proteinurie and the albuminuria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Proteinuric Diseases</condition>
  <arm_group>
    <arm_group_label>PBA 7,5g/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBA 15g/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PBA 7,5g/d</intervention_name>
    <description>Treatment for 14 days with PBA</description>
    <arm_group_label>PBA 7,5g/d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PBA 15g/d</intervention_name>
    <description>Treatment for 14 days with PBA</description>
    <arm_group_label>PBA 15g/d</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic Kidney disease for ore than 3 months&#xD;
&#xD;
          -  Proteinuria &gt; 1g/d or 0,1g/mmmol creatinine&#xD;
&#xD;
          -  eGFR &gt;30ml/mn/1,73m2&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
          -  affiliated with social security health insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with childbearing potential&#xD;
&#xD;
          -  Recent (&lt;3 months) modification of ACE inhibitors or ARB&#xD;
&#xD;
          -  Acute renal failure&#xD;
&#xD;
          -  eGFR &lt;30ml/mn/1,73m2&#xD;
&#xD;
          -  Nephrotic syndrome (albuminélia &lt;30g/l)&#xD;
&#xD;
          -  Infection with HIV, HCV, HBV&#xD;
&#xD;
          -  Liver insufficiency&#xD;
&#xD;
          -  No affiliated with social security health insurance&#xD;
&#xD;
          -  inclusion in another protocol of biomedical research&#xD;
&#xD;
          -  risk of non-adherence to protocol and visits&#xD;
&#xD;
          -  patients having a cardiac insufficiency of grade 3 or 4&#xD;
&#xD;
          -  patient requiring of a strict salt-free diet&#xD;
&#xD;
          -  patients under corticoids or immunosuppresseurs&#xD;
&#xD;
          -  clinical intolerance in the treatment&#xD;
&#xD;
          -  intolerance in the fructose, the syndrome of malabsorption glucose and galactose or a&#xD;
             deficit in sucrase / isomaltase&#xD;
&#xD;
          -  patients treated by Probenecide&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertrand KNEBELMANN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Néphrologie Adulte, Hôpital Necker</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>January 15, 2015</study_first_submitted>
  <study_first_submitted_qc>January 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2015</study_first_posted>
  <last_update_submitted>August 25, 2016</last_update_submitted>
  <last_update_submitted_qc>August 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Proteinuria</keyword>
  <keyword>Lipocalin 2</keyword>
  <keyword>Neutrophil gelatinase associated lipocalin</keyword>
  <keyword>ELISA</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

